Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
obligations may continue. See		

OMB APP	ROVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Celebi John					2. Issuer Name and Ticker or Trading Symbol Sensei Biotherapeutics, Inc. [ SNSE ]								ck all app	ship of Reporting Pa applicable) irector		Person(s) to Issuer 10% Owner			
(Last)	`	rst) (i	Middle)		3. Date of Earliest Transaction (Month/Day/Year)  02/15/2023  X Officer (give title below)  President a									t and (	Other (s below) CEO	pecify			
1405 RESEARCH BLVD, SUITE 125				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) ROCKVILLE MD 20850														X	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City)	(Si	ate) (2	Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - Noı	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	3ene	ficial	y Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution D		Date,	3. Transaction Code (Instr. 8)						Securit Benefic Owned	. Amount of ecurities eneficially wned Following eported		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)		Price	Transa	ransaction(s) nstr. 3 and 4)			(Instr. 4)
Common	Stock			02/15/	2023		F <sup>(1)</sup>		20,492	D \$1		\$1.5	5 110,811			D			
		Tal									osed of, o				Owne	d			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  Security  3. Transaction Date Execution Date, if any (Month/Day/Year)			4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Disport of (D	of Expi		s. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D Se (II	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code V (A) (D)		(D)	Date Exercis	able	Expiration Date	Title	Amou or Numl of Share	ber						

## **Explanation of Responses:**

1. Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

## Remarks:

/s/ Mark Ballantyne, Attorney-09/11/2023 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.